middle.news
Aroa Biosurgery Drives Record Myriad Sales Amid Strong Cash Flow and Steady FY25 Outlook
6:22am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Aroa Biosurgery Drives Record Myriad Sales Amid Strong Cash Flow and Steady FY25 Outlook
6:22am on Monday 2nd of June, 2025 AEST
Key Points
Second consecutive quarter of positive operating cash flow of NZ$1.1 million
Record monthly Myriad sales of US$2 million in March 2025, up 32% year-on-year
Maintained FY25 revenue guidance of NZ$76-79 million (constant currency) and EBITDA profit guidance
Strong demand for OviTex with 17% sales growth to partner TelaBio
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Aroa Biosurgery (ASX:ARX)
OPEN ARTICLE